Navigation Links
Nordic Nanovector: Share Options Granted, Including Options to Primary Insiders
Date:2/2/2017

OSLO, Norway, Feb. 02, 2017 /PRNewswire/ -- The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 1th of February 2017 decided to grant 719,500 share options to employees in accordance with the proxy given by the Annual General Meeting held on 19 May 2016. Each option, when exercised, will give the right to acquire one share in Nordic Nanovector. The options are granted without consideration.

The options will expire after 7 years. The vesting schedule means that 25% of each option holder's options will vest 12 months after the day of grant as long as the option holder is still employed. Thereafter, 1/36 of the remaining options will vest each month as long as the option holder is still employed, with the first 1/36 vesting 13 months after the day of grant. The exercise price of the options is NOK 90.37. The exercise price is equal to the volume weighted average trading price of the shares of the Company quoted on the Oslo Børs the last five days prior to the date of the grant.

Primary insiders that were granted options have the following holdings of options and shares in the Company after the new share options were granted on 1th of February 2017 (new options in parenthesis):

Luigi Costa, CEO holds 1,338,106 options (250,000) and owns 79,115 shares

Tone Kvåle, CFO holds 315,000 options (105,000) and owns 179,608 shares including shares to related party

Marco Renoldi, COO holds 464,137 options (96,000) and owns 74,000 shares

Anniken Hagen, CTOO holds 177,000 options (35,000) and owns 63,858 shares

Lisa Rojkjaer, CMO holds 375,000 options (35,000) and owns 2,186 shares

Rita Dege, CHRO holds 67,000 options (35,000) and owns 4,754 shares

Jostein Dahle, CSO holds 150,000 options (15,000) and owns 204,958 shares including shares to related party

The options allocated to the management of the Company is in accordance with the Board of Director's Declaration on salaries and other remuneration to the senior executive management, as approved by the Company's annual general meeting held 19 May 2016. The total number of outstanding share options is now 3,509,676 equivalent to 6.7 % of outstanding shares and options on a fully diluted basis.

For further information, please contact:

Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com

This information is subject to duty of disclosure pursuant to Section 5-12 and 4-2 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector--share-options-granted--including-options-to-primary-insiders,c2178912

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nordic-nanovector-share-options-granted-including-options-to-primary-insiders-300401079.html


'/>"/>
SOURCE Nordic Nanovector
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Nordic Nanovector to Present at Biotech Showcase 2017
2. AMRA, BerGenBio et Nexstim reçoivent les prix Nordic Stars 2015 lors des NLSDays à Stockholm
3. Verleihung des Nordic Stars 2015 Awards an AMRA, BerGenBio und Nexstim auf den NLSDays in Stockholm
4. AMRA, BerGenBio and Nexstim Receive Nordic Stars 2015 Awards at NLSDays in Stockholm
5. Nordic Building Constructors Industry Report by Researchmoz
6. Intense Competition Propelling Nordic Builders Merchants Industry
7. Nordic Life Science Days - Successful International Life Science Business Meeting in the Nordic Countries
8. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
9. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
10. One Million Solutions in Health and Choices & Patterns Share Research about Type 1 Diabetes – What Does it Take to be in Control of Blood Sugar?
11. Industry Experts Share their Insights on the Adoption Process of Novel Technologies in Drug Safety: Challenges and Solutions – Creating a Road Map for the Pharma Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Kathy Goin is joining myClin ... years of expertise in establishing and leading clinical operations at Sponsors including Trevena, ... therapist, through a variety of leadership roles in Clinical Operations, to her current ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop ... in downtown Boston at 745 Atlantic Ave. , “We are seeing that even ... the value they provide, not just to patients, but also payers. Having a presence ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is ... trial and error process by finding the right antidepressant faster. CNSDose speeds ... doctor-patient relationship through a personalized approach to treatment. , A peer-reviewed ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u ... Cooking Challenge is a two-hour team-building package designed for groups of 10-30 people. ... Jodi Abel, which include items, such as Blackened Shrimp with Edamame Salad, Pizza ...
Breaking Biology Technology:
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
Breaking Biology News(10 mins):